European Journal of Clinical Pharmacology

, Volume 74, Issue 5, pp 619–626 | Cite as

Antipsychotics use: 2006–2013 trends in prevalence and incidence and characterization of users

  • François Montastruc
  • Anne Bénard-Laribière
  • Pernelle Noize
  • Elodie Pambrun
  • Fabienne Diaz-Bazin
  • Marie Tournier
  • Bernard Bégaud
  • Antoine Pariente
Pharmacoepidemiology and Prescription



The present study was conducted to describe antipsychotic (AP) prevalent and incident use, characteristics of AP users, and their trends in the French population.


A cross-sectional study was repeated yearly from January 1, 2007 to December 31, 2013 (for prevalence analysis) or to December 31, 2012 (for incidence analysis) using the French Health Insurance reimbursement database (Echantillon Généraliste de Bénéficiaires, EGB). For each year studied, prevalent and incident AP users were described in terms of age and gender overall, and according to the type of AP (FGAPs or SGAPs) used at index date. In addition, concurrent medications and comorbidities that a priori contraindicate the use of drugs having atropinic properties were researched.


Prevalence and incidence remained relatively stable along the 2007–2013 period. Trends slightly decreased, from 2.07% (n = 10,252) to 2.05% (n = 11,015) for prevalence, and from 0.73% (n = 3461) to 0.66% (n = 3363) for incidence, especially in elderly, in contrast of children and adolescents (+ 39% for prevalence, from 184 to 271). The number of coprescribed drugs was found high (median = 5) and remained constant over time. In 2013, about 7% of prevalent AP users presented with a comorbidity increasing the risk of atropinic ADRs, and 36% used at least one concurrent atropinic drug. In incident AP users, these numbers were of 8 and 29%, respectively.


The present study highlighted a marked shift from FGAPs toward SGAPs, as well as an increase in AP use in children and adolescents in France.


Pharmacoepidemiology Drug utilization Insurance health reimbursement Antipsychotics Prevalence Incidence 



The present study is part of the Drugs Systematized Assessment in real-liFe Environment (DRUGS-SAFE) research programme. This programme aims at providing an integrated system allowing the concomitant monitoring of drug use and drug safety in France. It is funded by the French Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM). This publication represents the views of the authors and does not necessarily that of the ANSM.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

228_2017_2406_MOESM1_ESM.docx (13 kb)
Table S1 (DOCX 12 kb)
228_2017_2406_MOESM2_ESM.docx (16 kb)
Table S2 (DOCX 16 kb)
228_2017_2406_MOESM3_ESM.docx (16 kb)
Table S3 (DOCX 15 kb)
228_2017_2406_MOESM4_ESM.docx (39 kb)
Figure S1 (DOCX 39 kb)
228_2017_2406_MOESM5_ESM.docx (26 kb)
Figure S2 (DOCX 26 kb)
228_2017_2406_MOESM6_ESM.docx (39 kb)
Figure S3 (DOCX 39 kb)


  1. 1.
    Rang HP, Dale MM, Ritter JM et al (2011) Rang & Dale’s Pharmacology, 7th edn. Churchill Livingstone, LondonGoogle Scholar
  2. 2.
    Cáceres MC, Peñas-Lledó EM, de la Rubia A et al (2008) Increased use of second generation antipsychotic drugs in primary care: potential relevance for hospitalizations in schizophrenia patients. Eur J Clin Pharmacol 64(1):73–76. CrossRefPubMedGoogle Scholar
  3. 3.
    Verdoux H, Tournier M, Bégaud B (2010) Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies. Acta Psychiatr Scand 121(1):4–10. CrossRefPubMedGoogle Scholar
  4. 4.
    Moncrieff J (2013) Magic bullets for mental disorders: the emergence of the concept of an ‘antipsychotic’ drug. J Hist Neurosci 22(1):30–46. CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Carton L, Cottencin O, Lapeyre-Mestre M, Geoffroy P, Favre J, Simon N, Bordet R, Rolland B (2015) Off-label prescribing of antipsychotics in adults, children and elderly individuals: a systematic review of recent prescription trends. Curr Pharm Des 21(23):3280–3297. CrossRefPubMedGoogle Scholar
  6. 6.
    Moulis G, Lapeyre-Mestre M, Palmaro A, Pugnet G, Montastruc JL, Sailler L (2015) French health insurance databases: what interest for medical research? Rev Med Interne 36(6):411–417. CrossRefPubMedGoogle Scholar
  7. 7.
    Tuppin P, de Roquefeuil L, Weill A, Ricordeau P, Merlière Y (2010) French national health insurance information system and the permanent beneficiaries sample. Rev Epidemiol Sante Publique 58(4):286–290. CrossRefPubMedGoogle Scholar
  8. 8.
    Aging Brain Care. Anticholinergic Cognitive Burden Scale—2012 Update. Available:
  9. 9.
    Laroche ML, Charmes JP, Bouthier F, Merle L (2009) Inappropriate medications in the elderly. Clin Pharmacol Ther 85(1):94–97. CrossRefPubMedGoogle Scholar
  10. 10.
    Ilyas S, Moncrieff J (2012) Trends in prescriptions and costs of drugs for mental disorders in England, 1998-2010. Br J Psychiatry 200(5):393–398. CrossRefPubMedGoogle Scholar
  11. 11.
    Nguyen TTH, Pariente A, Montastruc J-L, et al. An original pharmacoepidemiologic - pharmacodynamic method: application to antipsychotic-induced movement disorders. Br J Clin Pharmacol Published Online First: 30 September 2016.
  12. 12.
    Montastruc F, Palmaro A, Bagheri H, Schmitt L, Montastruc JL, Lapeyre-Mestre M (2015) Role of serotonin 5-HT2C and histamine H1 receptors in antipsychotic-induced diabetes: a pharmacoepidemiological-pharmacodynamic study in VigiBase. Eur Neuropsychopharmacol 25(10):1556–1565. CrossRefPubMedGoogle Scholar
  13. 13.
    Moncrieff J (2014) The medicalisation of ‘ups and downs’: the marketing of the new bipolar disorder. Transcult Psychiatry 51(4):581–598. CrossRefPubMedGoogle Scholar
  14. 14.
    Healy D (2006) The latest mania: selling bipolar disorder. PLoS Med 3(4):e185. CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Jones DR, Macias C, Barreira PJ, Fisher WH, Hargreaves WA, Harding CM (2004) Prevalence, severity, and co-occurrence of chronic physical health problems of persons with serious mental illness. Psychiatr Serv 55(11):1250–1257. CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Leucht S, Burkard T, Henderson J, Maj M, Sartorius N (2007) Physical illness and schizophrenia: a review of the literature. Acta Psychiatr Scand 116(5):317–333. CrossRefPubMedGoogle Scholar
  17. 17.
    Ganguly R, Kotzan JA, Miller LS, Kennedy K, Martin BC (2004) Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. J Clin Psychiatry 65(10):1377–1388. CrossRefPubMedGoogle Scholar
  18. 18.
    Geddes J, Freemantle N, Harrison P, Bebbington P (2000) Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 321(7273):1371–1376. CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Peluso MJ, Lewis SW, Barnes TRE, Jones PB (2012) Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs. Br J Psychiatry 200(5):387–392. CrossRefPubMedGoogle Scholar
  20. 20.
    Hugenholtz GWK, Heerdink ER, Stolker JJ, Meijer WE, Egberts ACG, Nolen WA (2006) Haloperidol dose when used as active comparator in randomized controlled trials with atypical antipsychotics in schizophrenia: comparison with officially recommended doses. J Clin Psychiatry 67(06):897–903. CrossRefPubMedGoogle Scholar
  21. 21.
    Tsai AC, Rosenlicht NZ, Jureidini JN, Parry PI, Spielmans GI, Healy D (2011) Aripiprazole in the maintenance treatment of bipolar disorder: a critical review of the evidence and its dissemination into the scientific literature. PLoS Med 8(5):e1000434. CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Verdoux H, Pambrun E, Cortaredona S, Tournier M, Verger P (2015) Antipsychotic prescribing in youths: a French community-based study from 2006 to 2013. Eur Child Adolesc Psychiatry 24(10):1181–1191. CrossRefPubMedGoogle Scholar
  23. 23.
    Gallini A, Andrieu S, Donohue JM, Oumouhou N, Lapeyre-Mestre M, Gardette V (2014) Trends in use of antipsychotics in elderly patients with dementia: impact of national safety warnings. Eur Neuropsychopharmacol 24(1):95–104. CrossRefPubMedGoogle Scholar
  24. 24.
    Vinogradov S, Fisher M, Warm H et al (2009) The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia. Am J Psychiatry 166(9):1055–1062. CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Brébion G, Bressan RA, Amador X et al (2004) Medications and verbal memory impairment in schizophrenia: the role of anticholinergic drugs. Psychol Med 34(2):369–374. CrossRefPubMedGoogle Scholar
  26. 26.
    Rehse M, Bartolovic M, Baum K, Richter D, Weisbrod M, Roesch-Ely D (2016) Influence of antipsychotic and anticholinergic loads on cognitive functions in patients with schizophrenia. Schizophr Res Treatment 2016:8213165. CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Palmaro A, Moulis G, Despas F, Dupouy J, Lapeyre-Mestre M (2016) Overview of drug data within French health insurance databases and implications for pharmacoepidemiological studies. Fundam Clin Pharmacol 30(6):616–624. CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • François Montastruc
    • 1
    • 2
  • Anne Bénard-Laribière
    • 1
    • 3
  • Pernelle Noize
    • 1
    • 3
  • Elodie Pambrun
    • 1
  • Fabienne Diaz-Bazin
    • 1
  • Marie Tournier
    • 1
  • Bernard Bégaud
    • 1
    • 3
  • Antoine Pariente
    • 1
    • 3
  1. 1.Inserm, Bordeaux Population Health Research Center, Team Pharmacoepidemiology, UMR 1219University BordeauxBordeauxFrance
  2. 2.Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, Pharmacoépidémiologie et d’Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, Faculté de Médecine de ToulouseCentre Hospitalier UniversitaireToulouseFrance
  3. 3.CHU Bordeaux, Pole de Santé Publique, Centre Régional de Pharmacovigilance de Bordeaux, Service de Pharmacologie MédicaleBordeauxFrance

Personalised recommendations